Amoxicillin vs placebo for WHO-defined non-severe pneumonia
Comparison of Oral Amoxicillin with Placebo for the Treatment of World Health Organization–Defined Nonsevere Pneumonia in Children Aged 2–59 Months: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial in Pakistan
Tabish Hazir, Yasir Bin Nisar, Saleem Abbasi, Yusra Pervaiz Ashraf, Joza Khurshid, Perveen Tariq, Rai Asghar, Asifa Murtaza, Tahir Masood, Sajid Maqbool Clinical Infectious Diseases, Volume 52, Issue 3, 1 February 2011, Pages 293–300, https://doi.org/10.1093/cid/ciq142
To evaluate the effectiveness of amoxicillin in children who presented with pneumonia as per WHO definition of respiratory symptoms plus fast breathing.
Severe pneumonia kills many children each year. However, there is also concern about antibiotic over- prescribing in milder cases where the infection may not be bacterial in origin.The WHO has a simplified protocol; children with cough and fast breathing (respiratory rate over 50 if <11 months or over 40> if 12-59 months) and no chest indrawing are defined as non-severe pneumonia. This enables less experienced healthcare professionals to treat this common condition. The authors are questioning the rationale of this approach
Mulit-centre double blind placebo controlled trial.
Hospitals in 3 cities in Pakistan
Children aged 2-59 months with fast breathing, or cough or difficulty breathing. If fulfilled criteria of non-severe pneumonia as per WHO algorithm were included. Excluded children with underlying chronic illness, history of >3 episodes of wheeze or recent antibiotic use. Respiratory rate measured twice and average taken.900 children enrolled
Intervention; 3 days of amoxicillin 15mg/kg every 8 hours
Control; equivalent placebo
Salbutamol and paracetamol given to both groups as required
Therapy failure at day 3; defined as lower chest indrawing or danger signs.
Treatment failure at day 5; fast breathing, chest indrawing or danger signs.
Relapse; signs of pneumonia at 6-14 days.
In per-protocol analysis at day 3, 31 (7.2%) of the 431 children in the amoxicillin arm and 37 (8.3%) of the 442 in the placebo group had therapy failure. This difference was not statistically significant (odds ratio [OR], .85; 95%CI, .50–1.43; P = .60).
The clinical outcome of those with WHO defined non-severe pneumonia is unchanged by amoxicillin administration. Further studies are needed in areas with higher incidence of pneumonia.
I like defintion of therapy failure; the reason we treat these milder cases with antibiotics is to try and prevent more serious pneumonia
.Double blinded large trial Treatment failure rate of 7-8% feels about right.
Pragmatic trial in a low-resource clinic setting, no use of imaging or blood work.
I could not see a power calculation
Large difference of treatment failure at day 5 between amoxicillin ( 13.5% [58 children]) and in the placebo group (17.6% [78 children]) and although not statistically significant this could be due to being underpowered for the outcome.
It would have been nice to have some idea what percentage of cases were genuine cases as per gold standard
My humble opinion
This study was an interesting use of a placebo controlled trial to examine a definition of pneumonia. It is effective as instead of comparing to a (potentially flawed) gold standard, it uses a measure of effectiveness of antibiotics to prevent severe pneumonia as a marker. Something we as clinicians should be much more interested in than if XR changes or the like. Interestingly, the more symptoms and signs the more likely they were to have treatment failure, but no one sign was predictive. My personal practice of using a large number of factors to differentiate a well child with likely viral illness and potentially slightly more unwell child with pneumonia will not change, I will also have a lower threshold still in patients who are less able to return to a healthcare facility. However, when putting systems in place for less trained healthcare staff to screen for pneumonia I would be more cautious about using respiratory rate as the sole qualifier for antibiotics.